Health Affairs This Week

Health Affairs Publishing's Jeff Byers welcomes Jeanne Lambrew of The Century Foundation to discuss her recent Forefront article exploring whether high deductibles and health spending accounts achieve their intended goals and how alternative approaches could improve healthcare affordability and access. On April 20th, join us for our upcoming Insider exclusive event exploring the evolution of the Medicare Advantage market featuring Sachin Jain, David Meyers, and Grace Mackleby.Also, check out our newest trend report focusing on the current state of prior authorization.Become an Insider today.Related Articles:Abandon—Don’t Expand—High-Deductible Plans Linked To Spending Accounts (Health Affairs Forefront)

Health Affairs' Jeff Byers welcomes Halle Tecco, investor, founder of Rock Health and professor at Columbia Business School, to the pod to discuss her new book, Massively Better Healthcare: The Innovator's Guide to Tackling Healthcare's Biggest Challenges. Their conversation explores why consumers are becoming a powerful force in healthcare, how innovation happens within complex systems, and what it takes to align technology, evidence, and incentives to drive meaningful change.Related Links:Order Massively Better Healthcare: The Innovator's Guide to Tackling Healthcare's Biggest ChallengesCheck out Halle's podcast, The Heart of Healthcare Podcast

Health Affairs' Jeff Byers welcomes Ben Ippolito of the American Enterprise Institute to the pod to discuss the growing debate over Medicare Advantage (MA) payments and coding intensity. They break down why MA plans typically receive higher federal payments than traditional Medicare, how diagnostic upcoding factors into that gap, and what a new study in Health Affairs Scholar reveals about policy changes aimed at reducing inflated coding. On March 24th, join us for our upcoming Insider exclusive event focusing on pharmacy benefit manager reform with Harvard Medical School's Benjamin Rome.Related Articles:An updated analysis of coding pattern differences in Medicare Advantage (Health Affairs Scholar)The Trouble With MedPAC (Wall Street Journal)The Higher Price Tag on Medicare Advantage (Wall Street Journal)Aligning The MedPAC And CMS Estimates Of Coding Intensity: The Importance Of The Risk Model And Trend (Health Affairs Forefront)Medicare Advantage growth decelerates as insurers shed members for 2026 (Healthcare Dive)

Health Affairs' Jeff Byers welcomes Deputy Editor Leslie Erdelack back to the pod to break down recent turbulence at the FDA following the departure of Vinay Prasad, whose decisions around rare‑disease gene therapies courted controversy. They explore the fast‑growing rare disease therapeutics market, why traditional clinical trials often don’t work for ultra‑rare genetic conditions, and the new FDA draft guidance for rare disease drug development. On March 24th, join us for our upcoming Insider exclusive event focusing on pharmacy benefit manager reform with Harvard Medical School's Benjamin Rome.Become an Insider to get access to this event, trend reports, cheat sheets, and exclusive newsletters.Related Articles:FDA vaccines chief who ran afoul of pharma to depart (Politico)Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care (PR Newswire)FDA NEWS RELEASE: FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases FDA illuminates new approval pathway for bespoke gene editing therapies (Fierce Biotech)One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma (The New England Journal of Medicine)